Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus recommendation of "Buy" from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $25.67.
A number of equities analysts recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 target price for the company. Chardan Capital dropped their target price on shares of Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, May 29th. Finally, Mizuho dropped their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th.
View Our Latest Stock Report on EYPT
Institutional Investors Weigh In On Eyepoint Pharmaceuticals
Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 3.8% in the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after acquiring an additional 1,797 shares during the last quarter. Arizona State Retirement System lifted its holdings in Eyepoint Pharmaceuticals by 12.7% during the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after buying an additional 1,877 shares in the last quarter. Legal & General Group Plc lifted its holdings in Eyepoint Pharmaceuticals by 4.4% during the 4th quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock valued at $345,000 after buying an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Eyepoint Pharmaceuticals by 39.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after buying an additional 1,940 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Eyepoint Pharmaceuticals by 16.1% during the 4th quarter. Invesco Ltd. now owns 15,657 shares of the company's stock valued at $117,000 after buying an additional 2,177 shares in the last quarter. Institutional investors own 99.41% of the company's stock.
Eyepoint Pharmaceuticals Stock Performance
Shares of NASDAQ EYPT traded up $1.01 during midday trading on Friday, reaching $10.96. The stock had a trading volume of 1,395,822 shares, compared to its average volume of 822,410. The stock has a 50-day moving average of $7.87 and a 200-day moving average of $7.09. The company has a market capitalization of $754.16 million, a price-to-earnings ratio of -4.55 and a beta of 1.67. Eyepoint Pharmaceuticals has a 12-month low of $3.91 and a 12-month high of $13.99.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.65). Eyepoint Pharmaceuticals had a negative net margin of 261.91% and a negative return on equity of 54.27%. The firm had revenue of $24.50 million during the quarter, compared to analysts' expectations of $8.84 million. As a group, analysts forecast that Eyepoint Pharmaceuticals will post -2.13 EPS for the current fiscal year.
Eyepoint Pharmaceuticals Company Profile
(
Get Free ReportEyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More
Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.
While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
